Novartis' Capmatinib (INC280) Receives FDA's Priority Review for METex14 Mutated Advanced Non-Small Cell Lung Cancer
Shots:
- The US FDA has accepted NDA and granted PR designation to Capmatinib as a 1L treatment for LA/m- MET exon 14 skipping (METex14) mutated NSCLC
- The NDA submission is based on GEOMETRY mono-1 P-II study that demonstrated ORR (67.9%) assessed by BIRC assessment per RECIST v1.1- mDOR (11.4 and 9.72 mos.) in treatment naïve and prior treated patients respectively
- Capmatinib (INC280) is an investigational- oral- potent and selective MET inhibitor with its expected review to be completed within 6mos. The therapy is licensed from Incyte in 2009- under which Novartis got WW exclusive development and commercialization rights for the therapy and certain back-up compounds in all indications
Click here to read full press release/ article | Ref: Novartis | Image: WSJ
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com